Parkinson Disease Genetic Test: LRRK2, GBA, SNCA, PRKN, and Results

Parkinson disease genetic testing looks for inherited variants that can cause Parkinson disease, raise susceptibility, or explain unusually early symptoms. The most commonly tested genes include LRRK2, GBA1, SNCA, PRKN, PINK1, PARK7, and VPS35, but they do not all work in the same way. A pathogenic SNCA or LRRK2 variant may follow dominant inheritance, two PRKN variants may cause recessive early-onset disease, and one GBA1 variant usually acts as a risk factor rather than a certain diagnosis. Testing can clarify a diagnosis, inform relatives, and identify eligibility for gene-focused research. It cannot predict the exact age of onset, symptom pattern, or rate of progression. A useful interpretation therefore requires the specific variant, laboratory methods, ancestry, age, clinical findings, and family history—not merely the name of a gene on a report.

• Parkinson disease usually reflects a combination of age, biology, environment, and genetics rather than one inherited cause.
• LRRK2 and GBA1 findings are relatively common in some ancestry groups but have incomplete penetrance.
• PRKN, PINK1, and PARK7 usually require pathogenic variants in both gene copies to cause disease.
• SNCA testing should include copy-number analysis because duplications and triplications can be disease-causing.
• A variant of uncertain significance does not diagnose Parkinson disease or justify predictive testing in relatives.
• A negative panel does not rule out a genetic contribution.

Table of Contents

• What Parkinson genetic testing can answer
• Who may benefit from testing
• How the main Parkinson genes differ
• Laboratory methods that matter
• Reading positive, VUS, and carrier results
• Testing relatives without overpredicting risk
• Treatment, research, and practical decisions
• Negative results and next steps

What Parkinson genetic testing can answer

Genetic testing can identify a molecular contributor to Parkinson disease, but it is not the test used to establish whether a person currently has Parkinson disease. Diagnosis remains clinical, based on movement symptoms, neurologic examination, response to medication, disease course, and exclusion of other causes of parkinsonism. Imaging and laboratory studies may support the evaluation, but a genetic result must fit the clinical picture.

The test can answer several different questions:

• Does a person with Parkinson disease carry a pathogenic variant known to cause or increase susceptibility to the condition?
• Does very early onset suggest a recessive disorder such as PRKN-, PINK1-, or PARK7-related disease?
• Does a dominant family pattern point to LRRK2, SNCA, or VPS35?
• Could a GBA1 finding affect counseling, family planning, or eligibility for a clinical study?
• Can relatives receive targeted testing for a confirmed familial variant?

These questions are not interchangeable. Diagnostic testing in a person with symptoms differs from predictive testing in an unaffected relative. A positive result in someone who already has Parkinson disease may help explain cause, yet the same result in a healthy person may indicate only an age-dependent chance of future disease. Some pathogenic variants have reduced penetrance, meaning that not every carrier develops Parkinson disease.

Genetic testing also cannot convert a probability into a personal timetable. Even within the same family, carriers of an identical variant may differ in age at onset, tremor, gait problems, cognitive symptoms, medication response, and progression. Other genetic factors, exposures, overall health, and chance may modify expression.

The term “familial Parkinson disease” does not guarantee that testing will find one cause. Families can cluster because of shared variants, shared environment, multiple small genetic effects, or coincidence. Conversely, a person with no known family history may have a pathogenic variant because relatives died young, were misdiagnosed, had mild disease, did not inherit the variant, or carried it without developing symptoms.

A clinical panel should be distinguished from a research result or direct-to-consumer risk estimate. Clinical confirmation is generally needed before a finding guides medical or family decisions. Testing through a validated laboratory should specify the variant, classification, methods, and limitations.

Who may benefit from testing

Historically, testing was often limited to people with young onset, several affected relatives, or ancestry associated with particular founder variants. Those features still increase the chance of an informative result, but they do not capture every carrier. Large testing programs have identified reportable variants in people without the traditional risk factors. As gene-specific trials expand, clinicians increasingly discuss testing more broadly with people who have Parkinson disease.

Testing is especially worth considering when Parkinson disease begins before age 50, and particularly before age 40. Recessive PRKN, PINK1, and PARK7 disease is more likely in young-onset presentations. PRKN-related disease often begins with leg symptoms, dystonia, or a strong and sustained levodopa response, although no clinical feature is definitive. Extremely early or atypical parkinsonism may require a broader neurologic evaluation because many metabolic, developmental, and neurodegenerative genes can produce parkinsonism as one feature.

A family history also matters. Multiple affected people in successive generations may suggest dominant inheritance, raising attention to LRRK2, SNCA, or VPS35. Affected siblings with unaffected parents may suggest recessive inheritance, although dominant variants with reduced penetrance can create the same appearance. Details are more useful than a simple “yes” or “no”: record relatives with tremor, dementia, gait disorder, diagnosed Parkinson disease, age at onset, ancestry, and age at death.

Ancestry can change the probability of particular variants. LRRK2 p.G2019S occurs more often in people with North African Berber or Ashkenazi Jewish ancestry than in many other populations. Certain GBA1 variants are also enriched in Ashkenazi Jewish populations. These are tendencies, not boundaries. A person does not need a particular ancestry to carry a variant, and ancestry-based targeted testing can miss other important changes.

Testing may also be considered when the result could affect trial eligibility, reproductive planning, or relatives’ decisions. This does not mean the test will change current standard medication. The potential benefit should be balanced against uncertainty, emotional effects, family implications, privacy concerns, and the possibility of a VUS.

Unaffected adults who request testing because a relative has Parkinson disease should first determine whether an affected relative can be tested. Testing an affected person is more informative because a negative broad test in a healthy relative cannot show which familial factor was absent. When a pathogenic familial variant is known, targeted predictive genetic testing can answer whether the relative inherited that specific change.

Children are generally not tested for adult-onset Parkinson susceptibility when no childhood medical action follows. Testing can be appropriate in a child with juvenile parkinsonism or another active neurologic condition because the purpose is diagnostic rather than future-risk prediction.

How the main Parkinson genes differ

The gene name alone does not tell whether a result is dominant, recessive, high penetrance, or a susceptibility factor. The following distinctions are central to interpretation.

Gene	Typical role	Inheritance and key interpretation point
LRRK2	One of the most common identifiable monogenic contributors	Usually autosomal dominant with age-dependent, incomplete penetrance; variant-specific evidence matters
GBA1	Important Parkinson disease susceptibility gene; two pathogenic variants cause Gaucher disease	One pathogenic variant raises risk but does not make Parkinson disease certain
SNCA	Rare cause involving alpha-synuclein	Autosomal dominant; sequence variants, duplications, and triplications can be pathogenic
PRKN	Common cause of recessive young-onset Parkinson disease	Usually requires two pathogenic variants on opposite copies; exon deletions and duplications are important
PINK1	Rare recessive young-onset cause	Usually requires two pathogenic variants; one variant generally indicates carrier status
PARK7	Rare recessive young-onset cause	Usually requires two pathogenic variants; phenotype and phase must fit
VPS35	Rare dominant cause	Only specific variants have strong disease evidence; not every rare change is pathogenic

LRRK2: Pathogenic LRRK2 variants can produce Parkinson disease that resembles typical late-onset disease. The best-known variant is p.G2019S, but penetrance estimates vary with age, ancestry, study design, and possibly modifying factors. A carrier may remain unaffected into old age. This is why a separate LRRK2 result explanation should focus on the exact variant rather than treating every LRRK2 change as equivalent.

GBA1: One pathogenic GBA1 variant is associated with increased Parkinson disease risk, but many carriers never develop the condition. Risk and clinical associations vary by variant severity, ancestry, and age. Two disease-causing variants can establish Gaucher disease, which has its own systemic and neurologic implications. The laboratory must use methods that distinguish GBA1 from its nearby pseudogene. A detailed GBA genetic test interpretation is useful because carrier, Gaucher disease, and Parkinson susceptibility results are different conclusions.

SNCA: SNCA was the first gene definitively linked to familial Parkinson disease. Rare missense variants can be pathogenic, but dosage is especially important. A duplication or triplication of the gene can cause disease, and triplication has often been associated with earlier or more severe expression than duplication. Sequencing alone can miss these copy-number changes.

PRKN: PRKN-related disease usually requires pathogenic variants in both copies of the gene. These may be two sequence variants, two exon-level copy-number changes, or one of each. A single pathogenic PRKN variant usually means carrier status and does not by itself prove the cause of Parkinson disease. Some studies have investigated whether heterozygous carriers have increased susceptibility, but this question should not be overstated in a clinical report.

PINK1 and PARK7: These are rare autosomal recessive causes, most often associated with young onset. As with PRKN, two pathogenic variants generally must be confirmed in trans. One pathogenic variant is usually a carrier finding unless another variant or mechanism is discovered.

VPS35: The p.D620N variant is an established dominant cause in multiple families. Many other rare VPS35 variants lack comparable evidence. A laboratory should not classify a novel missense change as disease-causing simply because it occurs in the same gene.

Other genes can cause parkinsonism, but not all represent typical Parkinson disease. ATP13A2, PLA2G6, FBXO7, SYNJ1, DNAJC6, RAB39B, and several metabolic or neurodegenerative genes may be considered in early, complex, or atypical cases. Their inclusion should be guided by phenotype rather than an assumption that every parkinsonism gene carries the same meaning.

Laboratory methods that matter

A technically incomplete panel can produce a misleading negative result. Before testing, review whether the laboratory performs sequencing and deletion/duplication analysis, how it handles pseudogenes, and which regions have limited coverage.

Standard next-generation sequencing detects many single-nucleotide variants and small insertions or deletions. It may not reliably identify exon-level deletions, duplications, complex rearrangements, or low-level mosaicism. PRKN and SNCA make copy-number analysis particularly important. PRKN has frequent exon deletions and duplications; SNCA dosage changes can be the primary cause. A report that lists both genes but performs sequence analysis only is incomplete for their major disease mechanisms.

GBA1 is challenging because the highly similar pseudogene GBAP1 sits nearby. Recombination and gene-conversion events can create complex alleles. Laboratories may use long-range PCR, specialized alignment, confirmatory methods, or long-read approaches. A generic exome pipeline may mis-map reads or miss complex variants. The report should state whether full-gene GBA1 analysis and recombinant alleles were assessed.

For recessive genes, phase matters. Two variants in PRKN, PINK1, or PARK7 establish a recessive explanation only when they affect opposite gene copies. Testing parents or other relatives can show whether the variants are in trans. If both are on the same chromosome, the person may still have one unaffected copy and the findings do not explain recessive disease.

Some panels test only a short list of well-validated genes; others include dozens of parkinsonism and neurodegeneration genes. Broad testing may be appropriate for very early onset, atypical signs, intellectual disability, seizures, eye-movement abnormalities, pyramidal signs, neuropathy, liver disease, iron accumulation, or poor levodopa response. It also increases the chance of uncertain or unrelated findings. A phenotype-driven neurologic genetic panel may be more suitable than a narrow Parkinson panel in these cases.

Testing blood or saliva usually detects inherited germline variants. Mosaic variants limited to some tissues may be missed. The laboratory’s depth and reporting threshold should be considered if mosaicism is suspected.

Targeted founder-variant testing is less expensive but can miss most changes in a gene. For example, testing only LRRK2 p.G2019S does not exclude other pathogenic LRRK2 variants, and screening a limited set of GBA1 variants is not equivalent to full analysis. The test ordered should match the question stated in counseling.

Reading positive, VUS, and carrier results

A complete report should state the gene, transcript, DNA and protein change, zygosity, classification, method, and evidence. Interpretation then asks whether the variant’s mechanism and inheritance match the person.

A pathogenic or likely pathogenic dominant variant in LRRK2, SNCA, or VPS35 can provide a molecular diagnosis or strong causal explanation in a person with compatible Parkinson disease. “Likely pathogenic” is a technical evidence category, not a prediction that the person is likely to develop symptoms. In an unaffected person, penetrance remains a separate question.

A single pathogenic GBA1 variant in a person with Parkinson disease identifies a recognized genetic risk contributor. It does not establish that the variant was the sole cause, and it does not imply that every carrier relative will develop Parkinson disease. The report should also clarify whether a second GBA1 variant was sought and whether the person has features that warrant evaluation for Gaucher disease.

A biallelic pathogenic result in PRKN, PINK1, or PARK7 can establish recessive disease when the variants are in trans and the phenotype fits. One pathogenic variant in one of these genes is usually a carrier result. The clinician should verify whether deletion/duplication analysis was done before accepting that no second variant exists.

A variant of uncertain significance is not diagnostic. It should not be used to tell healthy relatives that they are destined to develop Parkinson disease, to make reproductive decisions, or to select an experimental treatment. Evidence may change through family segregation, functional research, larger population datasets, and expert review. Management should stay anchored to the clinical diagnosis.

A benign or likely benign variant does not explain disease. Common polymorphisms and research associations may appear in raw data but are not equivalent to clinically actionable findings.

Some people have more than one reportable variant. A GBA1 risk variant can coexist with a pathogenic LRRK2 variant, or a person may carry one recessive variant plus an unrelated risk allele. Each finding should be interpreted independently before considering possible combined effects. Evidence about interaction is often limited.

The report may also use terms such as “risk allele,” “reduced penetrance,” or “susceptibility variant.” These labels require quantitative context. Ask whether the evidence applies to the specific variant and ancestry, whether the result changes absolute risk, and whether the estimate comes from affected-case studies or population-based cohorts.

Testing relatives without overpredicting risk

A confirmed familial pathogenic variant creates an opportunity for targeted testing, but the meaning differs by gene. For a dominant LRRK2 variant, each child of a carrier has a 50% chance of inheriting the variant. That is not a 50% statement about developing Parkinson disease, because penetrance may be incomplete. SNCA and VPS35 variants also transmit in a dominant pattern, although penetrance and clinical severity are variant- and family-specific.

For recessive PRKN, PINK1, or PARK7 disease, full siblings of an affected person typically have a 25% chance of having the same biallelic condition, a 50% chance of being a carrier, and a 25% chance of inheriting neither familial variant when both parents are carriers. Those percentages apply to each pregnancy and assume the familial variants and parental phase are established. Children of an affected person generally inherit at least one pathogenic variant; their chance of disease depends on the other parent’s carrier status.

For GBA1, family counseling has two dimensions. One pathogenic variant may raise Parkinson disease susceptibility and also indicates carrier status for Gaucher disease. If both reproductive partners carry pathogenic GBA1 variants, each pregnancy can have a 25% chance of Gaucher disease. The type and severity of Gaucher disease are not predicted perfectly from genotype alone.

Predictive testing should be voluntary and informed. Counseling should cover uncertainty, possible anxiety, effects on family relationships, insurance rules that vary by country, data privacy, reproductive implications, and the limits of prevention. A negative targeted result can be reassuring when the familial variant is known, but it does not reduce all Parkinson risk to zero because common and nonfamilial disease remains possible.

Testing an unaffected relative with a broad panel before finding a variant in an affected family member is usually harder to interpret. A VUS cannot reliably identify who is at risk. Whenever possible, begin with the affected relative most likely to have an informative result.

Relatives should receive a copy of the exact report rather than a verbal summary such as “the family has a Parkinson gene.” Laboratories need the precise variant notation to order targeted testing and avoid testing the wrong change.

Treatment, research, and practical decisions

Most genetic findings do not currently replace standard Parkinson disease treatment. Levodopa and other medications, exercise, physical therapy, occupational therapy, speech and swallowing care, mental-health support, and management of sleep, autonomic, and cognitive symptoms remain based on the individual’s needs.

A result can nevertheless influence care. Some gene-associated forms have recognizable tendencies, such as young onset and sustained levodopa response in many people with PRKN-related disease. These are group patterns, not guarantees. The clinician should not withhold an effective therapy because a person’s experience differs from a published genetic profile.

The fastest-growing practical role of testing is research matching. Trials are studying therapies aimed at LRRK2 kinase activity, GBA1-related lysosomal pathways, alpha-synuclein, and other mechanisms. Eligibility may require a clinically confirmed variant, a particular disease stage, or additional biomarkers. A positive result does not guarantee access or benefit, and enrollment is not the same as approved treatment.

Genetic knowledge can also guide surveillance outside movement symptoms. Some GBA1 genotypes may prompt evaluation for Gaucher disease when compatible systemic features are present. Complex or atypical genetic parkinsonism may require monitoring for eye, liver, psychiatric, cognitive, neuropathic, or other manifestations. Recommendations should come from the specific diagnosis rather than a generic Parkinson panel.

The result may affect life planning. Families may consider reproductive testing, and healthy carriers may seek research monitoring. These choices should be made with realistic understanding of penetrance. There is no validated schedule of scans or blood tests that can tell an unaffected LRRK2 or GBA1 carrier exactly whether or when Parkinson disease will begin.

Privacy deserves attention before testing. Ask who stores the sample and data, whether de-identified data may be used for research, whether results enter the medical record, and what protections apply to health, life, disability, and long-term-care insurance in the relevant country. Research programs and clinical laboratories may have different consent and return-of-results policies.

Negative results and next steps

A negative Parkinson panel means no reportable variant was identified within the genes and methods used. It does not prove that genetics played no role. Most Parkinson disease is not explained by a single currently identifiable high-impact variant, and many common variants contribute small effects that routine clinical panels do not report.

First review test completeness. Did it include full sequencing of LRRK2, GBA1, SNCA, PRKN, PINK1, PARK7, and VPS35, or only selected founder variants? Did it assess PRKN and SNCA copy number? Was GBA1 analyzed with a method designed for the pseudogene and recombinant alleles? Were poorly covered regions listed? A negative answer to one of these questions can justify supplementary testing.

Second reconsider whether the phenotype is typical Parkinson disease. Early falls, vertical gaze palsy, prominent autonomic failure, rapid cognitive decline, cerebellar signs, upper-motor-neuron findings, seizures, neuropathy, liver disease, or poor levodopa response may indicate another parkinsonian syndrome. Very young onset can reflect Wilson disease, dopa-responsive dystonia, mitochondrial disease, lysosomal disease, neurodegeneration with brain iron accumulation, or another treatable or inherited disorder.

Third decide whether broader sequencing will address the remaining question. Exome or genome sequencing may identify rare genes not included on the panel, but standard short-read analysis still has limitations for repeat expansions, complex structural variants, mitochondrial heteroplasmy, and some noncoding changes. The next test should be selected from the specific gaps rather than ordered simply because it is larger.

Fourth ask about reanalysis. A negative result may become informative when a new gene-disease relationship is established or an old VUS is reclassified. Provide the laboratory with updated clinical information, especially if new neurologic or systemic features appear. Reanalysis cannot detect a variant type that the original assay never captured, so technical limitations must be revisited separately.

Finally, keep the result in perspective. A negative test does not change a well-supported clinical diagnosis of Parkinson disease, and a positive susceptibility result does not replace neurologic assessment. Genetic information is one layer of evidence. Its greatest value comes from matching the exact variant and laboratory method to the person’s phenotype, family, and goals.

References

• Parkinson’s Disease Variant Detection and Disclosure: PD GENEration, a North American Study (2024, Brain)
• Monogenic Parkinson Disease Overview (2025, GeneReviews)
• Genetic Testing of Movement Disorders: A Review of Clinical Utility (2024, Journal of Movement Disorders)
• Updated MDSGene Review on the Clinical and Genetic Spectrum of LRRK2-Related Parkinson Disease (2025, npj Parkinson’s Disease)
• Current Findings from PD GENEration (2026, Parkinson’s Foundation)
• Genetic Testing by Age at Onset in Parkinson Disease (2026, JAMA Neurology)

Disclaimer

This article provides general education and is not a diagnosis, risk calculation, or substitute for care from a neurologist, medical geneticist, or genetic counselor. Genetic results require review of the exact variant, laboratory methods, symptoms, ancestry, and family history. Do not change medication, surveillance, reproductive plans, or research participation based only on general information or an unconfirmed result.